

# Patrick Royston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/663291/publications.pdf>

Version: 2024-02-01

48  
papers

15,627  
citations

230014

27  
h-index

223390

49  
g-index

51  
all docs

51  
docs citations

51  
times ranked

28339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. BMC Medical Research Methodology, 2022, 22, 98.	1.4	3
2	Personalized Model to Predict Keratoconus Progression From Demographic, Topographic, and Genetic Data. American Journal of Ophthalmology, 2022, 240, 321-329.	1.7	7
3	A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. Trials, 2020, 21, 315.	0.7	21
4	Combined test versus logrank/Cox test in 50 randomised trials. Trials, 2019, 20, 172.	0.7	17
5	Meta-analysis of non-linear exposure-outcome relationships using individual participant data: A comparison of two methods. Statistics in Medicine, 2019, 38, 326-338.	0.8	22
6	Power and Sample-Size Analysis for the Royston-Parmar Combined Test in Clinical Trials with a Time-to-Event Outcome: Correction and Program Update. The Stata Journal, 2018, 18, 995-996.	0.9	2
7	Power and sample-size analysis for the Royston-Parmar combined test in clinical trials with a time-to-event outcome. The Stata Journal, 2018, 18, 3-21.	0.9	7
8	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ: British Medical Journal, 2017, 357, j2250.	2.4	67
9	A Combined Test for a Generalized Treatment Effect in Clinical Trials with a Time-to-event Outcome. The Stata Journal, 2017, 17, 405-421.	0.9	10
10	Reconstructing Time-to-event Data from Published Kaplan-Meier Curves. The Stata Journal, 2017, 17, 786-802.	0.9	157
11	Reconstructing Time-to-event Data from Published Kaplan-Meier Curves. The Stata Journal, 2017, 17, 786-802.	0.9	4
12	Reconstructing time-to-event data from published Kaplan-Meier curves. The Stata Journal, 2017, 17, 786-802.	0.9	36
13	A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome. The Stata Journal, 2017, 17, 405-421.	0.9	5
14	Mfpa: Extension of mfp Using the ACD Covariate Transformation for Enhanced Parametric Multivariable Modeling. The Stata Journal, 2016, 16, 72-87.	0.9	8
15	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. BMJ Open, 2016, 6, e011148.	0.8	13
16	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. BMC Medical Research Methodology, 2016, 16, 16.	1.4	51
17	mfpa: Extension of mfp using the ACD covariate transformation for enhanced parametric multivariable modeling. The Stata Journal, 2016, 16, 72-87.	0.9	4
18	The extension of total gain (TG) statistic in survival models: properties and applications. BMC Medical Research Methodology, 2015, 15, 50.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data. <i>BMC Medical Research Methodology</i> , 2015, 15, 82.	1.4	21
20	Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. <i>Statistics in Medicine</i> , 2015, 34, 2881-2898.	0.8	51
21	Estimating the Treatment Effect in a Clinical Trial Using Difference in Restricted Mean Survival Time. <i>The Stata Journal</i> , 2015, 15, 1098-1117.	0.9	15
22	Prognostic survival model for people diagnosed with invasive cutaneous melanoma. <i>BMC Cancer</i> , 2015, 15, 27.	1.1	22
23	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. <i>Trials</i> , 2014, 15, 314.	0.7	29
24	Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. <i>Statistics in Medicine</i> , 2014, 33, 4695-4708.	0.8	26
25	A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function. <i>The Stata Journal</i> , 2014, 14, 329-341.	0.9	3
26	Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis. <i>Statistics in Medicine</i> , 2013, 32, 3788-3803.	0.8	30
27	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. <i>BMC Medical Research Methodology</i> , 2013, 13, 152.	1.4	605
28	Tools to Simulate Realistic Censored Survival-Time Distributions. <i>The Stata Journal</i> , 2012, 12, 639-654.	0.9	11
29	A simulation study of predictive ability measures in a survival model I: Explained variation measures. <i>Statistics in Medicine</i> , 2012, 31, 2627-2643.	0.8	72
30	Multiple imputation using chained equations: Issues and guidance for practice. <i>Statistics in Medicine</i> , 2011, 30, 377-399.	0.8	6,168
31	The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. <i>Statistics in Medicine</i> , 2011, 30, 2409-2421.	0.8	363
32	Reporting methods in studies developing prognostic models in cancer: a review. <i>BMC Medicine</i> , 2010, 8, 20.	2.3	160
33	Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. <i>Lancet, The</i> , 2010, 375, 641-648.	6.3	117
34	Further Development of Flexible Parametric Models for Survival Analysis. <i>The Stata Journal</i> , 2009, 9, 265-290.	0.9	590
35	Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials. <i>The Stata Journal</i> , 2009, 9, 230-251.	0.9	49
36	Prognosis and prognostic research: Developing a prognostic model. <i>BMJ: British Medical Journal</i> , 2009, 338, b604-b604.	2.4	906

#	ARTICLE	IF	CITATIONS
37	Prognosis and prognostic research: what, why, and how?. <i>BMJ: British Medical Journal</i> , 2009, 338, b375-b375.	2.4	952
38	Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots. <i>Journal of the National Cancer Institute</i> , 2008, 100, 92-97.	3.0	36
39	Modelling to extract more information from clinical trials data: On some roles for the bootstrap. <i>Statistics in Medicine</i> , 2007, 26, 4989-5001.	0.8	18
40	Explained Variation for Survival Models. <i>The Stata Journal</i> , 2006, 6, 83-96.	0.9	238
41	Dichotomizing continuous predictors in multiple regression: a bad idea. <i>Statistics in Medicine</i> , 2006, 25, 127-141.	0.8	1,711
42	The design of simulation studies in medical statistics. <i>Statistics in Medicine</i> , 2006, 25, 4279-4292.	0.8	529
43	A Menu-driven Facility for Complex Sample Size Calculation in Randomized Controlled Trials with a Survival or a Binary Outcome: Update. <i>The Stata Journal</i> , 2005, 5, 123-129.	0.9	31
44	A new measure of prognostic separation in survival data. <i>Statistics in Medicine</i> , 2004, 23, 723-748.	0.8	371
45	Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. <i>Statistics in Medicine</i> , 2004, 23, 907-926.	0.8	101
46	A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. <i>Statistics in Medicine</i> , 2004, 23, 2509-2525.	0.8	234
47	Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. <i>Statistics in Medicine</i> , 2002, 21, 2175-2197.	0.8	1,062
48	Simplifying a prognostic model: a simulation study based on clinical data. <i>Statistics in Medicine</i> , 2002, 21, 3803-3822.	0.8	107